Skyrizi Patent Expiration: A Timeline of Risankizumab's Exclusivity
Skyrizi, a medication containing the active ingredient risankizumab, is a prescription treatment for various inflammatory autoimmune diseases, including psoriatic arthritis, Crohn's disease, and plaque psoriasis [1]. The medication is marketed by AbbVie and Janssen Biotech, Inc. The patent expiration date of Skyrizi is the primary concern of this analysis.
What is the Patent Expiration Date of Skyrizi?
According to the FDA and DrugPatentWatch.com [2], the patents for risankizumab, the active ingredient in Skyrizi, are scheduled to expire in the following years:
- The US patent for risankizumab expires on July 18, 2041 (US Patent No. 11,130,844).
- The European patent for risankizumab expires on August 28, 2041 (EP Patent No. EP 342,841).
- The Canadian patent for risankizumab expires on October 31, 2050 (CA Patent No. 3,062,111).
How Does Skyrizi Patent Expiration Affect Patients?
As the patent expiration date approaches, generic versions of risankizumab will likely be introduced to the market. This may lead to increased competition and potentially lower prices for Skyrizi. However, patients should be cautious of potential generic version quality and effectiveness.
Are Biosimilars an Option Before Patent Expiry?
Biosimilars, also known as follow-on biologics, are highly similar copies of existing biologic drugs. While the exact timeline for biosimilar approval is difficult to predict, it is likely that biosimilars for risankizumab will be approved before the patent expiration date. However, the timeline and regulatory pathway for biosimilar approval are still unclear.
Competitors and Alternatives
Several competitor medications to Skyrizi already exist or are in development. For example, Stelara (ustekinumab) and Cosentyx (secukinumab), also biologics, are used to treat similar conditions. As patent expiration approaches, patients, healthcare providers, and manufacturers should be aware of emerging competition.
Sources
[1] - AbbVie and Janssen Biotech, Inc. (2022). Skyrizi: Full Prescribing Information.
[2] - DrugPatentWatch.com (2023). Risankizumab Patent Expiration Dates.
Additional Information
* Consult with a healthcare professional for personalized advice on Skyrizi and potential alternatives.
* Monitor regulatory updates and scientific research on Skyrizi and emerging competitors.
* Be aware of potential generic version quality and effectiveness when available.